View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 30, 2020

Medtronic reports positive data from study of Evolut TAVR System

Medtronic has reported positive data from the Low Risk Bicuspid Study, which evaluates the use of the Evolut transcatheter aortic valve replacement (TAVR) system in patients with bicuspid aortic valve stenosis at low surgical risk.

Medtronic has reported positive data from the Low Risk Bicuspid Study, which evaluates the use of the Evolut transcatheter aortic valve replacement (TAVR) system in patients with bicuspid aortic valve stenosis at low surgical risk.

The 150-patient single-arm study reported low rates of all-cause mortality or stroke at 30 days (1.3%) with a low rate of serious procedural complications.

It also showed a 95.3% device success rate and a low rate of serious procedural complications, including no annular ruptures or aortic dissection.

In addition, the outcomes showed a low rate of all-cause mortality and a low rate of disabling stroke.

The study co-primary investigator Basel Ramlawi said: “These findings point to potentially less invasive treatment for patients who otherwise would undergo open-heart surgery due to their anatomical valve structure.

“We feel confident that these primary early outcomes provide additional evidence that the Evolut TAVR platform is a suitable treatment option for patients with bicuspid valves who have previously been left out of TAVR trials.”

The Evolut TAVR platform includes the Evolut R, Evolut PRO and Evolut PRO+ TAVR Systems.

It is indicated for symptomatic severe aortic stenosis (AS) patients across extreme, high, intermediate and low-risk categories and for Bicuspid valve patients at intermediate risk.

AS affects 1.5 million individuals globally and is one of the most common valvular heart diseases in the world.

Bicuspid aortic valve disease (BAVD) is a congenital heart defect, affecting approximately 2% of the general population. It is an abnormality of the aortic valve, leaving the patient with two functional valve leaflets instead of the more common three leaflets (tricuspid).

Patients with BAVD were generally excluded from prior TAVR trials due to concerns of asymmetric calcification, an elliptical shape, potential incomplete valve expansion, procedural technical concerns and other risk factors.

In September 2019, Medtronics launched the Evolut PRO+ TAVR System in the US, following its approval from the Food and Drug Administration (FDA).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network